AQR Capital Management
PBYI icon

AQR Capital Management’s Puma Biotechnology PBYI Stock Holding History

AQR Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.88M Sell
725,192
-75,002
-9% -$549K ﹤0.01% 1894
2026
Q1 		$5.11M Buy
800,194
+133,589
+20% +$861K ﹤0.01% 1731
2025
Q4 		$3.97M Buy
666,605
+535,933
+410% +$2.85M ﹤0.01% 1714
2025
Q3 		$694K Sell
130,672
-11,101
-8% -$47.1K ﹤0.01% 2640
2025
Q2 		$486K Buy
141,773
+91,315
+181% +$291K ﹤0.01% 2623
2025
Q1 		$149K Buy
50,458
+39,641
+366% +$124K ﹤0.01% 2943
2024
Q4 		$33K Buy
+10,817
New +$31.5K ﹤0.01% 2832
2018
Q4 		– Sell
-29,911
Closed -$1.37M – 2251
2018
Q3 		$1.37M Sell
29,911
-14,912
-33% -$719K ﹤0.01% 1566
2018
Q2 		$2.65M Buy
44,823
+951
+2% +$55.1K ﹤0.01% 1294
2018
Q1 		$2.98M Sell
43,872
-1,349
-3% -$101K ﹤0.01% 1185
2017
Q4 		$4.47M Sell
45,221
-3,040
-6% -$340K ﹤0.01% 1074
2017
Q3 		$5.78M Buy
48,261
+30,056
+165% +$2.8M 0.01% 966
2017
Q2 		$1.59M Buy
+18,205
New +$1.02M ﹤0.01% 1483
2016
Q3 		– Sell
-13,410
Closed -$399K – 2281
2016
Q2 		$399K Buy
13,410
+3,513
+35% +$110K ﹤0.01% 1941
2016
Q1 		$291K Buy
9,897
+334
+3% +$15.1K ﹤0.01% 2005
2015
Q4 		$750K Sell
9,563
-11,678
-55% -$917K ﹤0.01% 1699
2015
Q3 		$1.6M Sell
21,241
-4,782
-18% -$452K ﹤0.01% 1232
2015
Q2 		$3.04M Buy
26,023
+9,272
+55% +$1.68M 0.01% 1007
2015
Q1 		$3.96M Sell
16,751
-1,200
-7% -$257K 0.01% 870
2014
Q4 		$3.4M Buy
17,951
+2,662
+17% +$591K 0.01% 1052
2014
Q3 		$3.65M Sell
15,289
-90,400
-86% -$18.6M 0.01% 967
2014
Q2 		$6.97M Buy
105,689
+68,300
+183% +$4.86M 0.02% 758
2014
Q1 		$3.89M Sell
37,389
-25,800
-41% -$3.03M 0.01% 955
2013
Q4 		$6.54M Buy
63,189
+1,373
+2% +$80.6K 0.02% 758
2013
Q3 		$3.32M Buy
61,816
+54,501
+745% +$2.94M 0.01% 996
2013
Q2 		$325K Buy
+7,315
New +$258K ﹤0.01% 2066

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management's PBYI Position: Q2 2026 in Review

AQR Capital Management reduced its Puma Biotechnology (PBYI) stake by 9.4% in Q2 2026, selling an estimated $549K and leaving 725,192 shares worth $5.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1894.

AQR Capital Management first reported a position in PBYI in Q2 2013 and has held it in 26 quarters since. The position peaked at $6.97M in Q2 2014. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • AQR Capital Management held 725,192 shares of Puma Biotechnology worth $5.88M as of Q2 2026.
  • AQR Capital Management sold 75,002 Puma Biotechnology shares in Q2 2026, an estimated $549K.
  • Puma Biotechnology made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1894 holding.
  • AQR Capital Management first reported a position in Puma Biotechnology in Q2 2013 and has held it in 26 quarters since.
  • AQR Capital Management's Puma Biotechnology position peaked at $6.97M in Q2 2014.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.